Aralez Pharma (ARLZ): Catalysts Ahead - Guggenheim

Guggenheim analyst, Louise Chen, reiterated her Buy rating on shares of Aralez Pharmaceuticals (NASDAQ: ARLZ) and commented on upcoming catalysts for the company. The analyst expects approval of Yosprala on its PDUFA date on 9/14. ARLZ has been preparing for the launch by expanding its cardiovascular salesforce and launching promotional efforts for its other cardiovascular drugs. If approved, the company should launch the drug in 4Q16. She estimates peak sales of $200MM by '22, which is not fully reflected in consensus expectations.

For an analyst ratings summary and ratings history on Aralez Pharmaceuticals click here. For more ratings news on Aralez Pharmaceuticals click here.

Shares of Aralez Pharmaceuticals closed at $4.69 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• American International Group (AIG) PT Raised to $89 at Piper Sandler
• QuantumScape (QS) PT Lowered to $6 at Truist Securities